Harpreet Singh

Harpreet Singh, Ph.D. is the Co-Founder, Managing Director and Chief Scientific Officer at immatics biotechnologies GmbH. Harpreet founded immatics in 2000 during his Ph.D.

Being a scholar of Prof. Hans-Georg Rammensee, his first responsibility was translating innovative scientific concepts at the University of Tuebingen into a business model eventually leading to the closing of several venture capital financing rounds.

Harpreet is dedicated to the translation of science into highly innovative cancer immunotherapeutics. As CSO at immatics, Harpreet has set up and is responsible for units performing antigen discovery, CMC, immunomonitoring/ biomarker studies in multi-center clinical trials and translational early-stage clinical studies.

Harpreet also has a deep interest in personalized cancer immunotherapy (being coordinator of a novel EU-funded consortium for actively personalized vaccine treatment in glioma) and regulatory research (being founding member and co-chair of the Regulatory Research Group of the Association of Cancer Immunotherapy – CIMT).

Trained in chemistry and biochemistry, Harpreet completed his studies with his Ph.D. in Immunology at the University of Tuebingen.

Harpreet Singh is the CEO, Managing Director at immatics biotechnologies, based in Europe. With a background in Biotechnology, Harpreet Singh has a rich history of leadership and innovation.Harpreet Singh studied Ph.D. Immunology at University of Tuebingen. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.